Table 2.
CCS activity and clinical outcomes of 3680 IBD patients before and during COVID-19 outbreak.
| Pre- COVID-19 (January–February 2020) |
During COVID-19 (March–April 2020) |
p | Delta (during versus pre COVID-19 period) |
|
|---|---|---|---|---|
| Inbound calls, (n) | 881 | 971 | p < 0.02 | +10.2% |
| Number of outpatient visits, (n) | ||||
| -Scheduled | 270 | − | NA | − |
| -Urgent | 80 | 50 | p < 0.01 | −37.5% |
| Number of missed appointments, (n) | 25 | − | NA | |
| Number of virtual visits, (n) | − | 259 | NA | |
| Biologics infusions, (n) | 307 | 296 | p = 0.64 | −3.6% |
| Biologics infusions (per day), mean ± SD | 7 ± 1.63 | 7 ± 1.3 | p = 0.9 | |
| Overall hospitalisation, (n) | 158 | 96 | p < 0.01 | −39.2% |
| - New DH access | 36 | 12 | p < 0.05 | −66.7% |
| - Scheduled DH | 99 | 72 | p = 0.03 | −27.3% |
| - Elective Hospitalisation | 13 | 0 | p < 0.01 | − |
| -Urgent hospitalisation | 10 | 12 | p = 0.67 | +20% |
| Surgeries, (n) | 10 | 9 | p = 0.82 | −10% |
CCS, contact centre service; COVID-19, coronavirus disease 2019; DH, day hospital; IBD, inflammatory bowel disease; NA, not applicable; SD, standard deviation; yr, years.